ImpeDx Wins NSF Phase 2 Funding to Continue Developing AST Platform

September, 2018

ImpeDx Diagnostics is pleased to announce the Company has been awarded a Phase 2 SBIR from the National Science Foundation (NSF) to expand upon our completed Phase 1 SBIR, furthering the product development efforts towards our Rapid Antibiotic Susceptibility (AST) platform for pathogenic infections in blood, urine, sputum, and other human sample types.    “Our Phase 1 program demonstrated our capabilities in multiple sample types and on a variety of pathogen types, stated Roy Swiger, Sr VP of R&D. Click here for the NSF SBIR Seedfund Homepage

 

ABOUT IMPEDX DIAGNOSTICS

Overland Park, KS – ImpeDx Diagnostics (a privately held company) is developing a multiplexed phenotypic diagnostic system to perform extremely rapid Antibiotic Susceptibility Testing (AST) on a variety of different patient sample types (blood, urine, sputum, etc.) that will allow clinicians to provide targeted, effective antibiotics to patients in hours, rather than days or weeks as with currently available products.   Our system compliments existing rapid pathogen identification systems already on the market and provides the full answer clinicians require in order to implement appropriate patient care, improving patient outcomes while substantially reducing healthcare costs and the fostering of antibiotic resistance.  For more information, visit www.impedx.com.

CONTACT:

ImpeDx Diagnostics

Dr Roy R Swiger, CEO

roy@impedx.com